CONy 2021 | Predictive markers for CGRP-directed antibody treatment success in migraine

Piero Barbanti, MD, PhD, IRCCS San Raffaele Pisana, Rome, Italy, discusses the need for the characterization of patient phenotypes that predict the success of CGRP-directed monoclonal antibody treatment in migraine. Data from clinical studies have deepened our understanding of CGRP-directed monoclonal antibody treatment, with clinical responses being elicited in around 60% of migraine patients. However, predictive markers that indicate whether patients will be non- or super-responders need to be identified. Super responders refer to patients who experience at least a 75% reduction in migraine days. Developing predictive markers for CGRP-directed antibody treatment success will improve the treatment of migraine by making individualized treatment possible. This interview was conducted during the virtual 2021 CONy meeting.